- Home
- AGEN vs LPSN Comparison
AGEN vs LPSN Comparison
Compare AGEN & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- LPSN
- Stock Information
- Founded
- AGEN 1994
- LPSN 1995
- Country
- AGEN United States
- LPSN United States
- Employees
- AGEN N/A
- LPSN N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- LPSN EDP Services
- Sector
- AGEN Health Care
- LPSN Technology
- Exchange
- AGEN Nasdaq
- LPSN Nasdaq
- Market Cap
- AGEN 96.2M
- LPSN 93.0M
- IPO Year
- AGEN 2000
- LPSN 2000
- Fundamental
- Price
- AGEN $2.83
- LPSN $0.85
- Analyst Decision
- AGEN Buy
- LPSN Hold
- Analyst Count
- AGEN 3
- LPSN 6
- Target Price
- AGEN $10.50
- LPSN $1.18
- AVG Volume (30 Days)
- AGEN 566.5K
- LPSN 1.7M
- Earning Date
- AGEN 11-12-2024
- LPSN 11-07-2024
- Dividend Yield
- AGEN N/A
- LPSN N/A
- EPS Growth
- AGEN N/A
- LPSN N/A
- EPS
- AGEN N/A
- LPSN N/A
- Revenue
- AGEN $160,427,000.00
- LPSN $334,736,000.00
- Revenue This Year
- AGEN N/A
- LPSN N/A
- Revenue Next Year
- AGEN $36.13
- LPSN N/A
- P/E Ratio
- AGEN N/A
- LPSN N/A
- Revenue Growth
- AGEN 59.00
- LPSN N/A
- 52 Week Low
- AGEN $2.50
- LPSN $0.45
- 52 Week High
- AGEN $19.69
- LPSN $3.98
- Technical
- Relative Strength Index (RSI)
- AGEN 39.40
- LPSN 44.08
- Support Level
- AGEN $2.65
- LPSN $0.77
- Resistance Level
- AGEN $3.85
- LPSN $0.92
- Average True Range (ATR)
- AGEN 0.29
- LPSN 0.06
- MACD
- AGEN -0.02
- LPSN 0.00
- Stochastic Oscillator
- AGEN 15.00
- LPSN 38.45
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation.. The Conversational Cloud, the Company's enterprise-class digital customer conversation platform, is trusted by the world's top brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United Kingdom, Asia-Pacific, Latin America, and Europe.